Breast Cancer Tissue: Secretory breast cancer

NCT02938793: Durvalumab in Combination With Tremelimumab in Subjects With Advanced Rare Solid Tumors

NCT02938793
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: Inflammatory breast cancer (IBC), Secretory breast cancer
Recruitment Status: Recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with previous treatment of durvalumab, tremelimumab, or any checkpoint inhibitor including anti-CTLA-4 or anti-PD-1/L1 (e.g. Keytruda/pembrolizumab, Tecentriq/atezolizumab); Patients with untreated central nervous system metastatic disease
https://ClinicalTrials.gov/show/NCT02938793

NCT02650401: Study of RXDX-101 in Children With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions

NCT02650401
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: NTRK, ALK, ROS
Breast Cancer Tissue: Secretory breast cancer
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 2 Years to 22 Years (Child, Adult)
Location of Metastases: Brain
Additional Notes: Patients with solid tumors with or without NTRK, ROS, or ALK fusions are eligible
Exclusions: Patients over the age of 22
https://ClinicalTrials.gov/show/NCT02650401

Up ↑